BlackRock Health Sciences Term Trust (BMEZ) Announces Expiration and Preliminary Results of Tender Offer
MWN-AI** Summary
BlackRock Health Sciences Term Trust (BMEZ) recently announced the expiration and preliminary results of its tender offer, which aimed to repurchase up to 40% of its outstanding common shares. The tender offer commenced on March 21, 2025, and concluded at 5:00 p.m. Eastern time on April 17, 2025. Preliminary data indicates that shareholders tendered 38,753,713 shares out of the 40,502,046 shares available for repurchase. Since the tender offer was undersubscribed, the Fund plans to purchase all properly tendered shares, with the purchase price set at 99.5% of the Fund's net asset value (NAV) as of April 21, 2025.
The results are deemed preliminary and subject to adjustment, and the final results will be disclosed around April 21. Shareholders seeking information regarding the tender offer have been advised to contact Georgeson LLC, acting as the Information Agent for the tender offer.
The announcement clarifies that this press release is intended for informational purposes and does not constitute an offer or recommendation to purchase shares. The tender offer was conducted in compliance with SEC regulations, with related documents available on the SEC's website. BlackRock emphasizes its commitment to investor well-being and financial technology, providing support to individuals in building savings for the future.
Investors are encouraged to check BlackRock’s official website for updates on Fund performance and other related information. The press release also included a cautionary note regarding forward-looking statements, highlighting the potential risks and uncertainties that could affect actual results compared to projections made by the Fund or BlackRock.
MWN-AI** Analysis
The BlackRock Health Sciences Term Trust (BMEZ) recently announced the expiration and preliminary results of its tender offer to repurchase up to 40% of its outstanding common shares. The results indicate that 38,753,713 shares were tendered, slightly under the 40,502,046 shares offered for repurchase. This undersubscription means that shareholders will receive the number of shares they tendered, at a purchase price set at 99.5% of the Fund’s net asset value (NAV) as of April 21, 2025.
From an investment perspective, the challenge lies in interpreting the implications of this tender offer. The undersubscription signals a potential lack of confidence among investors regarding the Fund’s long-term performance or market conditions. Shareholders opting to sell their shares at a near-NAV price reflects a cautious approach towards risk exposure in the health sciences sector.
Investors should assess the factors contributing to this sentiment, including broader market volatility, interest rate fluctuations, or potential disruptions in the healthcare industry. Moreover, as the Fund expects to announce final results shortly, this creates an opportunity for investors to analyze any subsequent market reactions, particularly concerning the Fund’s overall performance moving forward.
In conclusion, while the tender offer's preliminary results might indicate some investor hesitance, they could also provide strategic opportunities for discerning investors. Purchasing shares if they dip in response to perceived negative sentiment could be beneficial, especially if the underlying fundamentals of the health sciences sector remain robust. Thus, staying aligned with market updates and final results will be essential for managing investment risk associated with BMEZ.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
BlackRock Health Sciences Term Trust (the “Fund”) announced today the expiration and preliminary results of the Fund’s tender offer (the “Tender Offer”) for up to 40% of its outstanding common shares (the “Shares”).
The Tender Offer commenced on March 21, 2025 and expired at 5:00 p.m. Eastern time on April 17, 2025.
Based on preliminary information, the number of Shares properly tendered and not withdrawn is noted in the table below.
Fund Name | Ticker | CUSIP | Shares Offered for Repurchase | Shares Tendered (Preliminary Results) |
BlackRock Health Sciences Term Trust | BMEZ | 09260E105 | 40,502,046 | 38,753,713 |
Based on the preliminary results shown above, because the Tender Offer was undersubscribed, the number of Shares that will be purchased from each tendering shareholder is expected to equal the number of Shares properly tendered for the Fund. The purchase price of properly tendered and accepted Shares will be 99.5% of the Fund's net asset value (“NAV”) as of the close of regular trading on the New York Stock Exchange on April 21, 2025, the business day immediately following the expiration date of the Tender Offer. The above-indicated results are based on preliminary information, are subject to adjustment and should not be regarded as final. The Fund expects to announce the final results of its Tender Offer on or about April 21, 2025.
Questions regarding the Tender Offer may be directed to Georgeson LLC, the Information Agent for the Tender Offer, toll free at the numbers disclosed in the Fund’s Offer to Purchase.
Important Notice
This press release is for informational purposes only and shall not constitute a recommendation, an offer to purchase or a solicitation of an offer to sell any common shares of the Fund. The offer to purchase the Fund’s common shares was made only pursuant to an offer to purchase, a related letter of transmittal and other documents filed with the U.S. Securities and Exchange Commission (“SEC”) as exhibits to a tender offer statement on Schedule TO. Shareholders may obtain a free copy of the offer to purchase and other documents filed with the SEC at the website maintained by the SEC at www.sec.gov or by directing such requests to the Fund.
About BlackRock
BlackRock’s purpose is to help more and more people experience financial well-being. As a fiduciary to investors and a leading provider of financial technology, we help millions of people build savings that serve them throughout their lives by making investing easier and more affordable. For additional information on BlackRock, please visit www.blackrock.com/corporate
Availability of Fund Updates
BlackRock will update performance and certain other data for the Fund on a monthly basis on its website in the “Closed-end Funds” section of www.blackrock.com as well as certain other material information as necessary from time to time. Investors and others are advised to check the website for updated performance information and the release of other material information about the Fund. This reference to BlackRock’s website is intended to allow investors public access to information regarding the Fund and does not, and is not intended to, incorporate BlackRock’s website in this release.
Forward-Looking Statements
This press release, and other statements that BlackRock or the Fund may make, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act, with respect to the Fund’s or BlackRock’s future financial or business performance, strategies or expectations. Forward-looking statements are typically identified by words or phrases such as “trend,” “potential,” “opportunity,” “pipeline,” “believe,” “comfortable,” “expect,” “anticipate,” “current,” “intention,” “estimate,” “position,” “assume,” “outlook,” “continue,” “remain,” “maintain,” “sustain,” “seek,” “achieve,” and similar expressions, or future or conditional verbs such as “will,” “would,” “should,” “could,” “may” or similar expressions.
BlackRock cautions that forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and BlackRock assumes no duty to and does not undertake to update forward-looking statements. Actual results could differ materially from those anticipated in forward-looking statements and future results could differ materially from historical performance.
With respect to the Fund, the following factors, among others, could cause actual events to differ materially from forward-looking statements or historical performance: (1) changes and volatility in political, economic or industry conditions, the interest rate environment, foreign exchange rates or financial and capital markets, which could result in changes in demand for the Fund or in the Fund’s net asset value; (2) the relative and absolute investment performance of the Fund and its investments; (3) the impact of increased competition; (4) the unfavorable resolution of any legal proceedings; (5) the extent and timing of any distributions or share repurchases; (6) the impact, extent and timing of technological changes; (7) the impact of legislative and regulatory actions and reforms, and regulatory, supervisory or enforcement actions of government agencies relating to the Fund or BlackRock, as applicable; (8) terrorist activities, international hostilities, health epidemics and/or pandemics and natural disasters, which may adversely affect the general economy, domestic and local financial and capital markets, specific industries or BlackRock; (9) BlackRock’s ability to attract and retain highly talented professionals; (10) the impact of BlackRock electing to provide support to its products from time to time; and (11) the impact of problems at other financial institutions or the failure or negative performance of products at other financial institutions.
Annual and Semi-Annual Reports and other regulatory filings of the Fund with the SEC are accessible on the SEC's website at www.sec.gov and on BlackRock’s website at www.blackrock.com , and may discuss these or other factors that affect the Fund. The information contained on BlackRock’s website is not a part of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250417574830/en/
1-800-882-0052
FAQ**
How does the undersubscription of the Tender Offer for BlackRock Health Sciences Trust II of Beneficial Interest BMEZ reflect investor sentiment about the Fund's future prospects?
What factors led to the preliminary results showing only 38,753,713 shares tendered for BlackRock Health Sciences Trust II of Beneficial Interest BMEZ against the 40,502,046 shares offered?
With the purchase price set at 99.5% of the Fund's NAV, how might this affect the overall performance and investor confidence in BlackRock Health Sciences Trust II of Beneficial Interest BMEZ moving forward?
What are the potential implications for shareholders if actual results of the Tender Offer for BlackRock Health Sciences Trust II of Beneficial Interest BMEZ differ significantly from the preliminary results?
**MWN-AI FAQ is based on asking OpenAI questions about BlackRock Health Sciences Term Trust of Beneficial Interest (NYSE: BMEZ).
NASDAQ: BMEZ
BMEZ Trading
0.2% G/L:
$14.67 Last:
178,684 Volume:
$14.60 Open:



